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Available online 24 April 2008APOBEC-mediated cytidine deamination of HIV-1 genomes during reverse transcription has been shown to be
a potent mechanism of host restriction for HIV-1 infection ex vivo and in vitro. However, this defense system
can be overcome by the viral protein Vif. Unlike other mechanisms of host restriction, the APOCEC–Vif
interaction leaves an imprint on integrated proviruses in the form of G→A hypermutation. In the current work
we systematically studied levels, contexts, and patterns of HIV-1 hypermutation in vivo. The analysis of 24
full-genome HIV-1 sequences retrieved from primary PBMCs, representing infections with several HIV-1
clades, and the inclusion of 7 cognate pairs of hypermutated/non-hypermutated sequences derived from the
same patient sample, provided a comprehensive view of the characteristics of APOBEC-mediated restriction in
vivo. Levels of hypermutation varied nearly 5-fold among the studied proviruses. GpG motifs were most
frequently affected (22/24 proviruses). Levels of hypermutation varied across the genome. The reported “twin
peak” pattern of hypermutation was observed in 18/24 hypermutants, but the remainder exhibited singular
non-conforming patterns. These data suggest considerable complexity in the interplay of host restriction and
viral defense during HIV-1 infection.
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Infection with the human immunodeﬁciency virus type 1 (HIV-1)
is characterized by an early and extensive damage of key histological
elements (the CD4+ cells), with a consequential loss of adaptive
immune functions than is usually irreparable (Graziosi et al., 1998).
This destruction occurs before the effectors of the adaptive immunity
can even be detected (Brenchley et al., 2004; Mehandru et al., 2004).
Especially during these early weeks, but still persisting throughout the
whole course of infection, elements of innate immunity have a key
role in controlling viral replication (Goff, 2004).
Only a few innate mechanisms of host restriction to HIV infection
have been described so far(Gonzalez et al., 2005; Liu et al., 1996;
Samson et al.,1996; Stremlau et al., 2004), and for each of them there is), mjanini@pesquisa.epm.br
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l rights reserved.a recognized viral mechanism of evasion (Braaten and Luban, 2001;
Connor et al.,1997). One of thesemechanisms of host restriction toHIV
infection is mediated by the members of the apolipoprotein B mRNA-
editing catalytic polypeptide (APOBEC) enzyme family, with deami-
nase activity. APOBEC3G (Sheehy et al., 2002) and APOBEC3F (Zheng
et al., 2004), and possibly other APOBECs (Rose et al., 2005), have been
shown to possess strong activity in preventingHIV infection, especially
in ex vivo models. These enzymes are incorporated into nascent viral
particles and act during the next infection cycle, when a transient
single-stranded DNA (ssDNA) replication intermediate form of the HIV
genome becomes exposed during reverse transcription (Harris and
Liddament, 2004). Deamination of cytidine to uracil predominantly
occurs on theminus strand intermediate (Lecossier et al., 2003), which
can be evidenced as guanine-to-adenine (G→A) changes in the plus
strand. Thus, the effect of the APOBECs is to destroy the viral genetic
information through extensive G→A substitution. HIV can counteract
APOBEC-mediated restriction through the expression of the product of
the vif gene. The Vif protein prevents the incorporation of APOBECs
into the nascent viral particle, targeting the host deaminase for
ubiquitylation and subsequent proteasomal degradation (Mehle et al.,
2004). The Vif-mediated exclusion of APOBECs spares the virus from
this host restriction system.
HIV genomes with APOBEC-mediated G→A changes can either be
degraded or can be integrated into the host chromosome. More than a
Table 1
Virtually complete hypermutated HIV-1 proviral sequences obtained from primary
clinical PBMCs
Strain Subtype Country Accession numbera
99TH.C1416Hyper B Thailand EF165363 (AY945711)
01TH.OUR033iHyper B/CRF01_AE Thailand EF165361 (AY358071)
00TH.C1705HYP CRF01_AE Thailand AY945715 (DQ789392)
99TH.C2266Hyp C/CRF01_AE Thailand AY945735 (AY262830)
98US.MSC5016Hyper C United States EF165359 (AY444801)
98UG57146Hyper D Uganda EF165364 (AF484513)
98UG57132 Hyper D Uganda EF165362 (AF484506)
00TH.R1496HYP CRF01_AE Thailand AY945729
00KE_KER2018 A Kenya AF457057
01TH.OUR700I CRF01_AE Thailand AY358058
00TH.C1468HYP CRF01_AE Thailand AY945714
00TH.C4141HYP CRF01_AE Thailand AY945723
02TH.OUR658I CRF01_AE Thailand AY358055
01TZBD28-11 A Tanzania EF165365
00TH.OUR736I CRF01_AE Thailand AY358054
99IL.99ET8 C Ethiopia AY255828
03TZ.CO783iHyper A Tanzania EF165366
00KE_KNH1214 A Kenya AF457071
99UGC27305 A Uganda AF484484
03TZ.CO883P C Tanzania AY734557
01TZ.BD24-8Hyper C Tanzania EF165360
99KE_KSM4023-29 A Kenya AF457076
01TH.OUR598I CRF01_AE Thailand AY358053
00KE_NKU3007 A Kenya AF457091
a Accession numbers of non-hypermutated sequences, retrieved from the same
sample, are provided in parenthesis.
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HIV sequences showing “extensive and monotonous base substitu-
tions of G→A” were ﬁrst recognized in primary or cultured viral
genomes, and they were termed HIV hypermutants (Vartanian et al.,
1991), based on the term previously coined by Pathak and Temin for
the spleen necrosis virus model (Pathak and Temin, 1990). Until the
discovery of the APOBEC restriction system, hypermutation was often
considered as an advantageous mechanism of HIV genetic variation
that could accelerate its escape from anti-retroviral drugs and
immune pressure (Diamond et al., 2001). HIV hypermutation has
also been attributed to different factors, including Taq polymerase-
(Overbaugh et al., 1996) or HIV reverse transcriptase (RT)-induced
errors, or imbalances in intracellular nucleotide pools during reverse
transcription (Martinez et al., 1994; Vartanian et al., 1994). However, in
each of these studies, experiments failed to generate in vitro
hypermutants exhibiting the dinucleotide contexts of G→A change
consistently observed in vivo or in co-cultures, namely GpG→ApG
(Fitzgibbon et al., 1993) and GpA→ApA (Vartanian et al., 1991). In
2002, before the discovery of the APOBEC restriction system, Janini et
al. reported a series of experiments inwhich they could systematically
retrieve, after ex vivo infection of primary human peripheral blood
mononuclear cells (PBMCs), HIV hypermutants bearing the same
signature changes observed in primary clinical materials (Janini et al.,
2001b). Moreover, they showed that the levels and contexts of
hypermutation could be modulated by altering the activation status of
substrate cells.
Recent studies of hypermutants retrieved from primary clinical
specimens, and those obtained ex vivo and in vitro, showed that the
levels of hypermutation were not evenly distributed throughout the
viral genome. The levels exhibited two increasing 5′-to-3′ clines,
peaking just upstream of the central and the 3′ poly-purine tracts
(PPT), the so-called “twin peaks”model (Janini et al., 2001a; Suspene
et al., 2006). These ﬁndings led to the description of a model for the
process of reverse transcription in which varying levels of hyper-
mutation are ascribed to the time of exposure of ssDNA (Yu et al.,
2004).
The recent years have seen a signiﬁcant increase in the research of
APOBEC–Vif interaction, which led to a broader insight on the subject.
New, though sometimes conﬂicting, models of regulation of APOBEC
expression (Peng et al., 2006; Sarkis et al., 2006; Ying et al., 2007) and
post-translational processing (Chiu et al., 2005; Kreisberg et al., 2006;
Soros et al., 2007; Stopak et al., 2007;Wanget al., 2007b), packaging into
nascent virions (Wang et al., 2007a; Xu et al., 2007), and mechanism of
cytidine deamination during reverse transcription have been proposed
(Chelico et al., 2006; Coker and Petersen-Mahrt, 2007; Iwatani et al.,
2007; Li et al., 2007;Miyagi et al., 2007), backedmostly by ex vivo and in
vitro experiments. Nevertheless, the correspondence of each of these
models to in vivo hypermutation remains to be evaluated. The fact that
hypermutated HIV genomes can be integrated into the host chromo-
some and later retrieved for examination opens a unique window into
this important host restriction mechanism, setting it apart from other
mechanisms where the outcome of the host–virus interaction has to be
deduced by indirect markers such as infection levels. So far, most of the
information regarding host restriction of HIV by APOBECs derives from
ex vivo and in vitro studies (Vartanian et al., 1991) or from partial
genome sequences obtained fromprimary clinical material (Janini et al.,
2001b; Simon et al., 2005), approaches subject to the rendering of an
incomplete picture.
Theobjective of the currentwork is to systematically study the levels,
contexts, and patterns of HIV hypermutation in vivo. The analysis of 24Fig. 1. Levels of hypermutation in HIV-1 proviral genomes. a) Adenine and guanine and b) Cy
203 non-hypermutated strains (small ﬁlled circles). c) Hypermutation index (HI). Using m
100 bp) was calculated for 24 hypermutants (large gray circles) and non-hypermutants (s
reference sequences from the same DNA sample. Bars represent the median. See text for defull-genome HIV sequences retrieved from primary PBMCs and
representing infections with several HIV-1 clades, and the inclusion of
7 cognate pairs of hypermutated/non-hypermutated sequences
sampled from the same patient specimens, provide a comprehensive
view of the marks left by APOBEC-mediated restriction in vivo.
Results
HIV-1 sequences
Twenty-four hypermutated HIV-1 full-genome sequences recov-
ered from primary PBMCs from sero-positive patients were studied
(Table 1). The hypermutants represented infections with HIV-1sub-
types A, B, C, D, CRF01_AE, and unique recombinant forms, and were
sampled in East Africa, Southeast Asia, and North America. Specimens
01TH.OUR598I, 01TH.OUR700I, and 00TH.OUR736I were obtained
within 6 months of sero-conversion and 01TH.OUR033iHyper and
02TH.OUR658I were obtained within 1–2 years of sero-conversion
(Tovanabutra et al., 2004). Dates of infectionwere not available for the
other samples.
In seven cases, a non-hypermutated cognate sequence (Table 1, top)
was retrieved from the same sample that had yielded the hypermutant.
Each of these cognate pairs clustered phylogenetically; the non-
hypermutants were the closest available matches to the hypermutants,
differing from the hypermutants mostly in G→A changes (data not
shown).
Hypermutated genomes exhibited premature stop codons in the
majority of their protein coding sequences, and showed character-
istically long branches in phylogenetic trees, as previously reported
(Arroyo et al., 2004, 2005; Dowling et al., 2002; Harris et al., 2003,
2002; Tovanabutra et al., 2004, 2005; Watanaveeradej et al., 2006).tidine and thymine content in sequences from 24 hypermutated (large open circles) and
ultiple non-hypermutated references, the HI (APOBEC-mediated G→A substitutions/
mall ﬁlled circles). Open circles depict the HI for pair-wise comparisons using normal
tails.
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The nucleotide composition of hypermutants was compared to that
of non-hypermutated reference strains, as described in Materials and
methods. The range of adenine content was signiﬁcantly higher among
hypermutants compared to normal reference strains (38.3–43.2% versus
36.3–37.7%, respectively; pb0.001) (Fig. 1a). The adenine increase was
directly proportional to the decrease in guanine (slope=−0.9887;
r2=0.9848). Levels of adenine varied widely among the hypermutant
strains, with increases of 3% to 16%, compared to reference sequences.
Cytidine and thymine levels varied within a narrow range and were
comparable in hypermutants and reference sequences (Fig. 1b).
Hypermutation can also be assessed by comparing aligned query
and reference sequences, and determining the rates of G→A change.
We devised a parameter termed the Hypermutation Index (HI), in
which G→A substitutions resulting from cytidine deamination by the
APOBECs are corrected for the “background” G→A mutations. In pairs
of normal, non-hypermutated genomes of HIV-1 matched for genetic
subtype, the rates of G→A versus A→G substitutions are equilibrated.
The balance of these rates in pair-wise comparisons among normal
sequences was narrowly distributed around zero (Fig. 1c, bottom left).
Thus, for pairs of hypermutated and normal genomes, the observed
G→A substitution rate can be corrected by subtraction of the A→GFig. 2. Preferred context of hypermutation. Using multiple non-hypermutated references
ApG→GpG) and GpA hypermutation (number of GpA→ApA substitutions−number of ApA→
hypermutants (small ﬁlled circles). Large open circles depict the GpG and GpA hypermutatio
the origin with different slopes are shown as a reference. See text for details.mutation rate to represent G→A substitutions attributed to APOBEC-
mediated hypermutation.
Fig. 1c shows the range of HI observed. Each hypermutated
sequence was evaluated using several normal reference sequences,
including those from the same DNA sample when available. HI
varied nearly 5-fold, ranging from 1.3 to 6.4 substitutions/100 bp.
The choice of a particular normal reference sequence did not
substantially impact these results; coefﬁcients of variation for HI
determined using different reference sequences of a given subtype,
or sequences from the same versus a different individual, did not
exceed 15% (data not shown). There were no obvious associations
between HI and the genetic subtype or the geographic origin of
hypermutated strains.
Contexts of hypermutation
In hypermutated sequences, the dinucleotide motifs for G→A
substitution are GpG and GpA, where the underline denotes the edited
base. These correspond to the reverse complements of the preferred
dinucleotide substrates of cytidine deaminases APOBEC3G and
APOBEC3F, respectively (Beale et al., 2004; Liddament et al., 2004).
In the studied sample set the vast majority of the G→A changes
occurred within these two dinucleotide contexts (data not shown). In, the levels of GpG hypermutation (number of GpG→ApG substitutions−number of
GpA substitutions) was calculated for 24 hypermutants (large gray circles) and non-
n values for pair-wise comparisons using cognate references. Diagonals radiating from
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the dinucleotide context of hypermutationwas assessed by computing
the number of GpG→ApG and GpA→ApA substitutions. In each case,
the values were corrected for background mutation by subtracting the
rates of ApG→GpG and ApA→GpA substitutions, respectively.
When performing pair-wise comparisons involving solely non-
hypermutated sequences, calculated values for GpG and GpA
hypermutation displayed a narrow distribution around 0.00 substitu-
tions/bp for both contexts (95% CI=−0.02 to −0.002, and 0.008 to 0.02
substitutions/100 bp, respectively) (Fig. 2).
When analyzing hypermutants, two separate clusters were
deﬁned. Twenty-two out of 24 hypermutants had GpG as the
preferred context. A wide variation in the ratio of GpG preference
over GpA was observed, ranging from ratios of 2:1 to nearly 20:1
(interquartile range=5:1 to 8:1).
The second cluster was represented by two strains (00TH.
R1496HYP and 98UG57146Hyper, respectively). Both of them had a
3:1 preference of GpA over GpG, and a relatively high HI compared to
the other group. In both clusters, the choice of reference did not affect
the HI or the context preference, with a coefﬁcient of variation lower
than 7% for comparisons involving the same hypermutant but
different references (data not shown). In each cluster, sequencesFig. 3. Abundance and frequency of hypermutation of tetranucleotidemotifs in HIV-1 proviru
containing GpG in 195 non-hypermutated nearly-full proviral HIV-1 genomes from differen
pApGpN+2 conversion as computed from 6 hypermutants compared to their non-hypermuta
and in vitro are shown, with their respective bibliographic reference. b) Relationship between
N−1pGpGpN+2→N−1pApGpN+2 substitution frequency in hypermutants. The resulting coefﬁci
text for details.with the highest hypermutation for the predominant context were
also the ones exhibiting the highest HIs (data not shown). Thus, GpG
was the preferred context in almost all of the hypermutant genomes
in primary PBMCs, with a wide range of hypermutation levels. A
preference for editing within the GpA motif was recorded, but rarely.
Previous reports, based ex vivo and in vitro experiments, have
shown that the sequence context for APOBEC-mediated hypermuta-
tion extends beyond the dinucleotide level (Beale et al., 2004; Yu et al.,
2004). Thus, we examined this large hypermutant dataset represent-
ing in vivo hypermutation for wider sequence contexts. The frequency
of G→A changes in tetranucleotides of the form N− 1pGpGpN+2 (where
the edited base is underlined, and N−1 and N+2 denote the bases
located at positions −1 and +2 relative to the targeted G, respectively)
was computed. To minimize the impact of background mutation,
only the 6 samples that had a predominant GpG hypermutation
context and for which a cognate non-hypermutated sequence was
available (Table 1) were studied. Fig. 3 shows the abundance of each
of the motifs in the non-hypermutated sequences, and their
frequency of hypermutation. Some tetranucleotides were over- or
under-represented, as expected from previous studies (Berkhout and
van Hemert, 1994). Adenine-containing motifs (green) were the most
abundant in non-hypermutated genomes, consistent with knownses. a) The colored circle represents the abundance of di-, tri-, and tetranucleotidemotifs
t subtypes and CRFs. The bars represent the median frequency of N−1pGpGpN+2→N−1-
ted cognates. Motifs previously shown to be preferred substrates of APOBEC3G ex vivo
abundance of N−1pGpGpN+2 motifs in non-hypermutated HIV-1 proviral genomes, and
ent of correlation is shown. Data is derived from the same cognate pairs as in Fig. 3a. See
Fig. 4. Hypermutation patterns of 18 HIV-1 hypermutants. Hypermutated sequences
were aligned with non-hypermutated references and a) the frequency of G→A
substitution/G content and b) the frequency of GpG→ApG substitution/GpG content
in sliding windows of 600 bp overlapping by 10 bp was calculated. Black lines depict the
median of measurements of the same hypermutants versus at least 10 references, and
the red line depicts the median between all hypermutants. In interest of clarity, the
levels of hypermutation shown in the y-axis were normalized to the maximum level in
each strain. Nucleotide positions are relative to HXB2 reference strain (GenBank
accession number K03455).
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Tetranucleotides containing CpG (blue) were the least frequent
because their cytidines tend to be methylated, leading to reduced
transcriptional activity (Cooper, 2000), and are under-represented in
eukaryotic genomes. We observed that the tetranucleotide contexts
of in vivo hypermutation were consistent with, but broader than
those identiﬁed ex vivo and in vitro (Beale et al., 2004; Yu et al.,
2004). Among the seven tetranucleotides preferred ex vivo and in
vitro, six were hypermutated at levels of 50% or greater in vivo
(Fig. 3a, and Supplemental Table 2). However, in vivo hypermutation
also occurred at rates between 30% and 50% in the context CpGpGpT,
identiﬁed ex vivo and in vitro, and in four newly identiﬁed preferred
contexts, namely GpGpGpA, CpGpGpA, ApGpGpA, and ApGpGpT.
They were low but measurable rates in TpGpGpC and GpGpGpT
contexts as well.
We tested the hypothesis that hypermutation had contributed to
the current base-composition bias in HIV, by depleting the cytidine
deaminases' preferred substrates. The frequency of each tetranucleo-
tide motif in HIV-1 was compared to its frequency of hypermutation,
but the analysis yielded no direct relationship between these two
factors (see Fig. 3b).
Patterns of hypermutation
We (Janini et al., 2001a) and others (Suspene et al., 2006) have
reported that the levels of hypermutation can be unevenly distributed
across HIV-1 genomes. A pattern of rising and falling levels has been
seen, ascribed to different durations of exposure of single-stranded
DNA to APOBECs during HIV replication. Too few complete viral
genomes have been analyzed to determine the consistency of this
pattern, and its range of variation. We applied a newly developed
software package, “HyperPack” (Kijak et al., 2007) to examine 203
normal, non-hypermutated (Supplemental Table 1) and 24 hypermu-
tated (Table 1) HIV-1 genomes for the pattern of hypermutation across
the genome.
First, the distribution of substrates for hypermutation across the
genomes was analyzed (Supplemental Fig. 1). Normal genomes
(n=203) were analyzed using SubstrateScan, which determined the
abundance of mono- or oligonucleotide motifs in a series of
overlapping, sliding windows. The G content averaged 24% and varied
from 20–27% in different genome regions. The average frequency of
the GpG dinucleotide across the genome was 7%, and the range of
variation was 4–9%. The motif GpA averaged 8% of dinucleotides, and
varied from 6–9% across the genome. Thus, the substrates of
hypermutation are abundant throughout the HIV-1 genome, albeit
with some small regional variations consistent among many different
isolates (Supplemental Fig. 1).
The distribution of hypermutation events was estimated across the
genome using HyperScan, a similar sliding-window approach that
determines what fraction of a given substrate, evaluated in a normal
reference strain or strains, is converted to product. We empirically
determined that windows of 600 bp overlapping by 10 bp provided
adequate signal-to-noise ratios (data not shown). For the HyperScan
of G→A substitutions, 18 of 24 hypermutated genomes showed a
consistent pattern (Fig. 4, top). Hyperscans of individual strains are
shown in Supplemental Fig. 2. Substitution levels were low at the
beginning of gag, and steadily increased until the RNAseH domain of
pol. The rate dropped dramatically, reaching a nadir at the 3′ end of
the integrase gene. Thereafter, levels again increased, mirroring the
pattern of increase in the 3′ half of the genome, until the end of gp41,
where they seemed to start diminishing. This patternwas reiterated in
the GpG→ApG HyperScans (Fig. 4, bottom), except for the presence of
two local minimums, in the middle of the RT coding region and in the
C3 domain of gp120, respectively. The GpA→ApA HyperScans showed
no consistent patterns among the strains analyzed (Supplemental
Fig. 2).Although consistent, the above-described hypermutation pattern
was not universal (Fig. 5). Six strains showed atypical patterns,
including the two GpA context hypermutants 98UG_57146 and
Fig. 5.Hypermutation patterns of 6 outlier HIV-1 hypermutants. Hypermutated sequences were aligned with non-hypermutated references and the frequency of G→A substitution/G
content (red), the frequency of GpG→ApG substitution/GpG content (green) and the frequency of GpA→ApA substitution/GpG content (blue) in sliding windows of 600 bp
overlapping by 10 bp were calculated. Each line represents the median of measurements of the same hypermutants versus at least 10 references. Nucleotide positions are relative to
HXB2 reference strain (GenBank accession number K03455).
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increase in hypermutation levels from the 5′ to the 3′ end of the
genome, with some inconsistent peaks and troughs. Three of the other
outliers were the two strains with the lowest overall levels of
hypermutation among those with GpG context preference, namely
00KE_NKU3007 and 01TH_OUR5981, and that with the second-to-
highest level, 00KE_KER2018. In the latter strain, therewas a relatively
constant level of hypermutation across the genome. Finally, strain
00TH_OUR736I had low hypermutation across the genome except for
a patch at the 3′ end of pol.
Overall, 18 of 22 strains with a preferred GpG hypermutation
context conformed to the “twin peak” pattern shown in Fig. 4.
Exceptionally high or low levels of GpG context hypermutation
seemed associated with aberrant patterns, as did the two hypermu-
tants with a preferred GpA context.
Evaluation of proposed models of APOBEC3G-mediated hypermutation
Recently, in vitro experiments performed on synthetic substrates
have led to a model of APOBEC3G-mediated deaminationwith a series
of sliding and jumping events (Chelico et al., 2006). Following random
binding of the APOBEC3G to the ssDNA substrate, the enzyme would
act processively 3′→5′ on the anti-sense strand, until structuralconstrains are found, which would lead to the jumping of the enzyme
to another region along the same genome. Patches of highly
hypermutated areas separated by stretches relatively devoid of
hypermutation would be expected from this model.
We analyzed cognate pairs where GpG was the preferred context
for the distribution of GpG sites and the local distribution of
hypermutation events. The GpG sites were dense in the genome. In
non-hypermutated sequences, 55% of the GpG sites were separated by
10 bp or fewer, with 40% of them being separated by 5 bp or fewer
(data not shown). We selected a few regions of the genome
representing different levels of hypermutation for a more detailed
analysis. The hypermutated sites tended to be spread evenly
throughout the area with no obvious alternation between highly-
edited patches and cold-spots (Supplemental Fig. 3).
Discussion
APOBEC3G and APOBEC 3F are expressed in the lymphoid cells that
are primary targets of HIV-1 infection in vivo, and their activity is
counterbalanced by a range of viral Vif variants (Harris and Liddament,
2004). The activities of APOBEC3G and APOBEC 3F are distinguishable
in part by their dinucleotide context for G→A substitution, GpG and
GpA, respectively (Bishop et al., 2004). This study used an analysis of
108 G.H. Kijak et al. / Virology 376 (2008) 101–111hypermutated complete HIV-1 proviral genomes recovered from
primary PBMCs to help dissect the relative contributions of different
APOBECs and the range of suppression mediated by Vif in vivo. While
previous studies reported results obtained in ex vivo or in vitro
experiments, the use of primary clinical materials permitted us to
preserve the imprints left in vivo by the APOBEC restriction system.
The main features of the APOBEC–Vif interaction identiﬁed here
include: 1) levels of hypermutation varying by nearly 5-fold, ranging
from 1.3 to 6.4 G→A substitutions/100 bp (Fig. 1c); 2) Preference for
the GpG context (22/24 strains), implicating APOBEC3G as a major
restricting element in the cells harboring HIV-1 provirus in the
bloodstream of infected individuals (Fig. 2); 3) Variable bias for the
GpG over the GpA context, ranging from 2:1 to nearly 20:1, which in
turn suggests variation in the relative contributions of APOBEC3G and
APOBEC3F in different hypermutated proviruses (Fig. 2); 4) Conﬁrma-
tion of the previously reported preferred tetranucleotide contexts for
GpG hypermutation and identiﬁcation of ﬁve additional substrates
converted at 25%–50% levels; and 5) Conservation of the “twin peak”
pattern of hypermutation across the genome at different levels of
hypermutation and identiﬁcation of non-conforming patterns, mainly
at the extremes of the range of hypermutation levels in GpG context,
and in both of the GpA context hypermutants identiﬁed. Overall, these
results suggest a wider range of APOBEC–Vif interactions than
previously appreciated, and show that examination of hypermutated
genomes provides new opportunity to gain insight into parameters
controlling levels, contexts, and patterns of hypermutation in vivo.
Moreover, these results help validate some of the proposedmodels for
APOBEC–Vif interaction.
The observed variation in levels of hypermutation may be
attributed to a number of factors, probably acting in concert: different
number of APOBEC molecules packaged in each viral particle,
polymorphic variants of APOBEC with different activities, variation
in the kinetics of reverse transcription that result in varying exposure
times of ssDNA substrate. APOBEC3F and -G are known to be
expressed at different levels depending on factors such as cell type
(Sarkis et al., 2006), cell activation (Peng et al., 2006), or HIV disease
stage (Jin et al., 2005, 2007). In turn, APOBECs are present within cells
mostly in two states, an inactive high-mass molecular (HMM) form,
and an active low-mass molecular form (LMM) (Chiu et al., 2005).
Mitogen activation can lead to the conversion from the LMM to the
HMM form, and is associated with rendering the activated cells
permissive to HIV infection (Stopak et al., 2007). Altogether, this
expression and post-translational regulation of APOBECs can result on
variable availability of these molecules for incorporation into the
nascent viral particle. Xu et al. have shown that delta-vif viruses
produced in culture carry in average between 3 and 11 APOBEC3G
molecules per virion (Xu et al., 2007). Thus, the nearly 5-fold variation
of hypermutation levels observed in vivo is generally consistent with a
4-fold variation of APOBEC content in viral particles. Moreover, the
small number of APOBEC particles incorporated per virionwould tend
to make the distribution of HI values behave as a discrete variable,
which is also apparent from our results. For instance, in our dataset 17/
24 hypermutants had HI that concentrated in the range of 2–3
substitutions/100 bp, probably reﬂecting the mode of the distribution
of number of APOBEC molecules per virion. Also, aberrant pattern of
genome-wide hypermutation observed at the extremes of HI
distribution may reﬂect the inclusion of a high number of APOBEC
molecules, leading to saturation of G→A substitution (strain 00KE.
KER2018), or incorporation of a very low number of APOBEC
molecules in the viral particle accompanied by low overall HI (strains
00KE.NKU3007 and 01TH.OUR598I). In the latter, and following the
model proposed by Soros et al., by which virion-incorporated
APOBEC3G is associated with HIV-1 genomic RNA but remains latent
until its activity is restored during reverse transcription by action of
HIV RNase H (Soros et al., 2007), incorporation of a very limited
number of APOBEC molecules will be manifested as genomes bearingsigniﬁcant marks of hypermutation in fewareas. Polymorphic variants
of APOBECmay also be responsible of varying levels of hypermutation,
but would not necessarily lead to the observed discrete distribution of
HI values.
In the current analysis, we were able to retrieve from primary
PBMCs strains predominantly carrying the GpGmotif. Janini et al. have
shown in ex vivo experiments that, by modifying cell activation
around the time of infection, the context of hypermutation can be
modulated (Janini et al., 2001b). According to their model, where GpG
was the predominant context of hypermutation in resting PBMCs but
the GpA context predominated in the genomes recovered after
activation, our results would seem to indicate that most of the
hypermutated proviruses that we retrieved might have derived from
viral particles produced in resting PBMCs. If that was the case,
APOBEC3G would be mediating the protection of resting PBMCs, and
APOBEC3F would be the restriction system acting in activated cells.
The underlying reasons for these phenomena are probably related to
different stimuli and mediators of the recruitment of LMM into HMM
form for each of the APOBECs, an important subject that remains to be
elucidated.
In our results it was evident that in each studied sequence there
was a clear predominance of one of the dinucleotide contexts over the
other, which was concordant with previously reported in vivo data
based on partial HIV genome sequences (Janini et al., 2001b; Simon et
al., 2005). The preference of APOBEC3G was estimated in vitro to be
2.5:1 for GpG versus GpA (Suspene et al., 2004), but the ratio of
context preference for APOBEC3F has not been yet systematically
addressed. In the sequences analyzed here exhibiting a predominant
GpG hypermutation context, the ratio of motif preference ranged from
2:1 to 20:1 in favor of GpG. Among the explanations that can be
proposed for this distribution is the occurrence of APOBEC3G in
human populations as allelic forms with different dinucleotide or
larger-context substrate speciﬁcity, or the concurrent involvement of
other members of APOBEC family, as homo- or heterodimers. Only a
limited number of representatives of the GpA-preferred motif were
detected in the current sample set, and their ratio of context
preference was 3:1 in favor of GpA. Interestingly, these two sequences
had also HI levels that were among the highest in the sample set,
suggesting that, while not a prevalent mechanism of restriction,
APOBEC3F hypermutation can be a very effective one.
In aggregate, the presence of two clearly separate clusters based on
dinucleotide context preference would support the hypothesis that
APOBEC3F and -G may not be naturally co-packaged into nascent
virions, at least in equivalent proportions for their respective active
forms. Our results contrast with the ex vivo experiments of Liddament
et al. (2004), that showed that both enzymes are co-expressed and
that they can act in concert in controlled experimental settings. Still, in
the latter, the burden of high enzyme concentration resulting from ex
vivo over-expression may have distorted the natural balance of host
restriction and viral defense mechanisms, and could have surpassed
the Vif-mediated APOBEC-exclusion system. In addition, the two
enzymes seem to have different sensitivities to Vif-mediated exclu-
sion (Liddament et al., 2004). It will be important to conduct
experiments that can clarify the relationship between natural
expression and regulation of the different members of the APOBEC
family and anti-retroviral restriction.
Ex vivo and in vitro experiments have shown that the context
preference of APOBECs extends beyond the dinucleotide level, and
tetranucleotide motifs have been identiﬁed, facilitated by the knowl-
edge of the sequence of the initial infecting strain in the controlled
experimental setting. Deducing preferred tetranucleotide motifs from
hypermutated sequences retrieved from primary clinical materials
can be hindered by the absence of closely related reference sequences.
Our results from the comparison of cognate sequence pairs from the
same sample were consistent with ex vivo and in vitro data (Beale
et al., 2004; Yu et al., 2004), reiterating the avoidance of APOBEC3G
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substrate for APOBEC3G in vitro was CGGG (Beale et al., 2004). We
showed that this motif was very infrequent in HIV genomes but, when
present, it was affected in more than 50% of its occurrences. We were
also able to identify ﬁve additional substrates converted at signiﬁcant
levels, which indicates that the available sites for APOBEC-mediated
hypermutation are extensively present throughout the viral genome.
Due to the small number of sequences exhibiting the GpA motif, we
could not clearly establish an extended context for APOBEC3F.
Even before the recognition of APOBECs as the elements
responsible for HIV hypermutation, it was described that G→A editing
did not follow an erratic conﬁguration (Janini et al., 2001a; Suspene
et al., 2006). A pattern that consisted in two ascending gradients in
5′→3′ direction, peaking at the central-PPT and 3′-PPT tracts,
respectively, was deﬁned in several HIV hypermutants. This pattern
was later ascribed to a replication model with two initiation sites for
the synthesis of the sense DNA strand during reverse transcription
(Suspene et al., 2006; Yu et al., 2004). According to this model, uneven
levels of hypermutation along the genome were due to the fact that
different genomic areas in the anti-sense strand remain as ssDNA for
different periods of time, as only ssDNA and neither ssRNA, RNA/DNA
heteroduplexes, nor dsDNA are subject to APOBEC-mediated deami-
nation (Suspene et al., 2004). While most of the genomes analyzed
would support this model, we did observe several exceptions, mostly
at the low and high extremes of the HI and in the GpA preference
hypermutants. Additional complexities of the APOBEC–Vif interaction,
stoichiometry of APOBEC incorporation into the viral particle (Xu
et al., 2007), the dynamics of reverse transcription and concurrent
degradation of the RNA template by the viral RNase H, which in turn is
intimately related to the activation of APOBECs (Soros, Yonemoto, and
Greene, 2007), may underlie these observations.
In the current study, we evidenced hypermutation as a phenom-
enon that occurs in multiple viral genetic subtypes and inter-subtype
recombinant forms, and in patients from diverse geographic areas. No
association was evident between any of the abovementioned factors
with the levels, contexts, or patterns of hypermutation. However, given
the extent of inter-clade variation in the vif gene and the limited
number of representatives of each clade included in the current study,
we cannot exclude the possibility that there are parameters of
hypermutation that vary in different populations and geographic
regions. Both the viral defense proteinVif (Pace et al., 2006) andhuman
APOBECs (Do et al., 2005; Valcke et al., 2006) are genetically variable.
Some forms of the Vif protein may be more efﬁcient than others when
preventing the incorporation of APOBEC molecules into the nascent
virion. In the same vein, some allelic variants of APOBECs may be less
susceptible to Vif. While polymorphism H186R in APOBEC3G was
associated with progression to AIDS in North America and Western
Europe (An et al., 2004), the molecular basis of this phenomenon
remains to be revealed, and the crucial interaction of APOBEC and Vif
warrants further studies on co-variation of these genes and the
potential for variable strategies of host restriction reﬂected bydifferent
levels and patterns of hypermutation, in different populations.
The APOBEC–Vif interaction is the only known host–virus restric-
tion system in HIV-1 biology where an imprint of outcome of the
event can be retrieved from infected cells. This added dimension
warrants continuing investigating HIV hypermutation for the infor-
mation it may provide leading to the manipulation of this interaction
in favor of the host.
Materials and methods
Studied hypermutated sequences
Twenty-four hypermutated HIV type 1 (HIV-1) virtually full-length
genome sequences were analyzed, each of them obtained from a
different patient. All of the sequences were retrieved from DNAextracted from primary PBMCs and without co-culture. Specimens
were sampled in the setting of HIV-1 global molecular epidemiology
studies. All of these sequences were retrieved through the same
standard protocol (see below), and they were recognized as
hypermutants immediately after obtainment, due to their extensive
G→A substitution levels. In 7 cases, cognate pairs of hypermutants/
non-hypermutated sequences retrieved from the same DNA sample
could be obtained, and these were used for analyses that required
closely matched hypermutated and normal reference sequences.
Ofﬁcial sequence names, HIV-1 clade assignment, country of sam-
pling, and accession numbers are indicated in Table 1. Sixteen of these
hypermutated sequences were reported previously (Arroyo et al.,
2004, 2005; Dowling et al., 2002; Harris et al., 2003, 2002;
Tovanabutra et al., 2004, 2005; Watanaveeradej et al., 2006) but had
not been analyzed in detail. No information regarding anti-retroviral
treatment history, plasma viral load, or CD4 cell counts was available.
Normal reference sequences
A total of 203 non-hypermutated full-genome HIV-1 sequences
retrieved from the Los Alamos Database (http://www.hiv.lanl.gov)
were used as normal references for analysis (Supplemental Table 1).
Sequences included subtypes A (n=39), B (n=11), C (n=69), D (n=30),
and CRF01_AE (n=54), and their proportions were balanced to reﬂect
the clade distribution in the hypermutant dataset.
Levels and contexts of hypermutation
Nucleotide base frequencies, substitution frequencies, and con-
texts of hypermutation were determined using the Bases, Substitu-
tions, and Context modules, respectively, implemented in HyperPack
(Kijak et al., 2007). For each hypermutant, levels and context of
hypermutation were assessed through pair-wise comparisons in
optimized alignments with at least 10 reference sequences matched
for HIV subtype, to control for within-clade genetic variation. Unique
recombinant forms (URFs) were compared only to their respective
cognate reference.
Levels of hypermutation were determined through the hypermu-
tation index (HI), deﬁned as:
HI ¼ GYA substitutions bpð Þ  AYG substitutions bpð Þ
sequence length bpð Þ
In the HI, the level of A→G substitution is used to correct for
background mutation.
Dinucleotide contexts of hypermutationwere determined through
the comparison of context-dependent HIs:
HIGpG ¼ GpGYApG substitutions bpð Þ  ApGYGpG substitutions bpð Þsequence length bpð Þ
and
HIGpA ¼ GpAYApA substitutions bpð Þ  ApAYGpA substitutions bpð Þsequence length bpð Þ
where the levels of ApG→GpG and ApA→GpA substitution are used to
correct for the HIV-1 RT contribution (background mutation) to
sequence variation.
The occurrence of tetranucleotidemotifs of the formN−1pGpGpN+2
in normal sequences, where N−1 and N+2 denote the bases located at
positions −1 and +2 relative to the targeted G, respectively, and their
corresponding frequencies of hypermutation to N−1pApGpN+2 were
assessed. The investigation ofwider contexts of hypermutation ismore
sensitive to the effects of background genetic variation, so only cognate
pairs, which represent the closest matches of query and reference
sequences, were used.
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The distribution of substrate motifs for hypermutation across the
HIV-1 genome, and their rates of APOBEC-mediated G→A conversion,
were determined using the SubstrateScan and HyperScan modules,
implemented in the HyperPack as previously described (Kijak et al.,
2007). Brieﬂy, optimizedpair-wise alignments of a queryanda reference
sequence are parsed into overlapping sliding windows, and the
occurrence of substrates (in SubstrateScan) and their rates of hypermu-
tation (in HyperScan) are computed. Each hypermutant was separately
compared to at least 10 reference sequences, matched for HIV subtype,
to control for within-clade genetic variation, except from URFs, which
were only compared to their respective cognate reference.
HIV-1 full-genome ampliﬁcation, sequencing and phylogenetic analysis
Sequences were retrieved from DNA extracted from primary
PBMCs, using the same standard full-genome ampliﬁcation method
by nested PCR by which non-hypermutated isolates are retrieved, and
as previously reported (Carr et al., 1999; Salminen et al., 1995b).
Nucleotide sequencing was carried out with big dye terminators using
an ABI 3100 capillary sequencer (Applied Biosystems Inc., Foster City,
CA), as described. Sequences were analyzed, edited, and assembled
with Sequencher 3.0 (Ann Arbor, MI). Phylogenetic analysis was
performed using the SEQBOOT, DNADIST, NEIGHBOR, CONSENSE
modules of the Phylip software package (distributed by Joseph
Felsenstein, Department of Genetics, University of Washington,
Seattle [ftp://evolution.genetics.washington.edu/pub/phylip/]), and
with TREETOOL (provided byMaciukenas S: Treetool, 2.0.2. Ribosomal
DNA Database Project, University of Illinois Board of Trustees, Urbana,
IL). Bootscanning (Salminen et al., 1995a) and sub-genomic neighbor
joining trees were used to characterize recombinant strains.
Statistical analysis
The analyses of the data distribution, Mann–Whitney U test, and
linear regressionwere performed using Prism 4.0 (GraphPad Software).
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